Effect of Compound Danshen Dripping Pills on cardiac function after acute anterior ST-segment elevation myocardial infarction:A randomized trial
Bo Deng1
Sibo Wang1
Yujie Wu1
Qiming Wang1
Rui Qiao2
Xiwen Zhang3
Yuan Lu4
Li Wang5
Shunzhong Gu6
Yuqing Zhang7
Kaiqiao Li8
Zongliang Yu9
Lixing Wu10
Shengbiao Zhao11
Shuanglin Zhou11
Yang Yang1
Liansheng Wang1
1.Department of Cardiology,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China2.Department of Cardiology,Anqing Municipal Hospital Affiliated to Anhui Medical University,Anqing,Anhui 246003,China3.Department of Cardiology,Huai'an First People's Hospital,Huai'an,Jiangsu 223300,China4.Department of Cardiology,the Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221006,China5.Department of Cardiology,Pukou Branch of Jiangsu People's Hospital,Nanjing,Jiangsu 211899,China6.Department of Cardiology,Hai'an People's Hospital,Nantong,Jiangsu 226699,China7.Department of Cardiology,the Affiliated Jiangning Hospital of Nanjing Medical University,Nanjing,Jiangsu 211199,China8.Department of Cardiology,Qixia District Hospital of Nanjing City,Nanjing,Jiangsu 210046,China9.Department of Cardiology,the First People's Hospital of Kunshan Affiliated to Jiangsu University,Kunshan,Jiangsu 215300,China10.Department of Cardiology,Nanjing Lishui District Hospital of Traditional Chinese Medicine,Nanjing,Jiangsu 211299,China11.Department of Cardiology,Nanjing Meishan Hospital,Nanjing,Jiangsu 210039,China
摘要：The current study aimed to evaluate the efficacy and safety of Compound Danshen Dripping Pills(CDDP)in improving cardiac function in patients with acute anterior ST-segment elevation myocardial infarction(AAMI).Between February 2021 and February 2023,247 eligible patients with AAMI after primary percutaneous coronary intervention were enrolled and randomly assigned(1∶1)to receive CDDP(n=126)or placebo(n=121),with a follow-up of 48 weeks.Compared with the placebo group,the CDDP group demonstrated a significant increase in left ventricular ejection fraction values after 24 weeks of treatment(least squares mean:3.31;95％confidence interval[CI]:1.72-4.90;P＜0.001)and at the 48-week follow-up(least squares mean:4.35;95％CI:2.76-5.94;P＜0.001).Significant reductions in N-terminal pro-B-type natriuretic peptide levels were observed in both groups at the 24-and 48-week visits with no significant difference between the two groups(P＞0.1 for all).The incidence of major adverse cardiovascular and cerebrovascular events was 6.35％in the CDDP group and 5.79％in the placebo group(P=0.822).Notably,no serious adverse events were attributed to CDDP.These findings suggest that CDDP may be well tolerated and could improve left ventricular ejection fraction in patients with AAMI at 24 and 48 weeks.
机标关键词：st-segmentcompoundfunctiontrialafteracuteanteriorcardiac
分类号：R542.2(心脏、血管（循环系）疾病)
论文发表日期：2025-07-30
在线出版日期：2025-10-11（本平台首次上网日期，不代表文献的发表时间）
页数：10( 407-416 )
英文信息